Cover Image
市場調查報告書

鼻病毒感染疾病:開發中產品分析

Rhinovirus Infections - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 257796
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
鼻病毒感染疾病:開發中產品分析 Rhinovirus Infections - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 49 Pages
簡介

鼻病毒是感冒的一般性原因。病毒的傳染途徑是咳嗽打噴涕等飛沫傳染。常見的症狀有喉嚨痛、鼻水、噴涕、倦怠感、頭痛、食欲不振等。危險因子有年齡、免疫力降低等。治療方法有止痛藥、鼻炎藥等。

本報告提供鼻病毒感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

鼻病毒感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • AIMM Therapeutics B.V.
  • Biological Mimetics, Inc.
  • Biota Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH
  • Johnson & Johnson
  • Novartis AG
  • Theraclone Sciences, Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BNT-014
  • KR-22809
  • Monoclonal Antibodies for Human Rhinovirus Infections
  • Monoclonal Antibody for Asthma, COPD and Rhinovirus Infections
  • Monoclonal Antibody for Human Rhinovirus Infections
  • OBR-5340
  • PL-402
  • Recombinant Peptide for Rhinovirus Infection
  • Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection
  • Small Molecules for Rhinovirus Infections
  • Small Molecules to Inhibit RNA Polymerase for Rhinovirus and Picornaviridae Infections
  • vapendavir

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9130IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhinovirus Infections - Pipeline Review, H1 2017, provides an overview of the Rhinovirus Infections (Infectious Disease) pipeline landscape.

Rhinoviruses are common cause of the common cold. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhinovirus Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rhinovirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhinovirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rhinovirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 6 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Rhinovirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rhinovirus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rhinovirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rhinovirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rhinovirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rhinovirus Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rhinovirus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rhinovirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rhinovirus Infections - Overview
    • Rhinovirus Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Rhinovirus Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rhinovirus Infections - Companies Involved in Therapeutics Development
    • AIMM Therapeutics BV
    • AstraZeneca Plc
    • Aviragen Therapeutics Inc
    • Biological Mimetics Inc
    • Boehringer Ingelheim GmbH
    • Novartis AG
    • Prokarium Ltd
  • Rhinovirus Infections - Drug Profiles
    • BNT-014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cetylpyridinium chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human rhinovirus (polyvalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KR-22809 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Viral 3C Protease for Human Rhinovirus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Human Rhinovirus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBR-5340 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-402 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polymer for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide to Inhibit Viral 2A Cysteine Protease for Rhinovirus Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rhinovirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PI4KB for Rhinovirus Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit 3C Protease for Rhinovirus Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vapendavir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VXX-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rhinovirus Infections - Dormant Projects
  • Rhinovirus Infections - Product Development Milestones
    • Featured News & Press Releases
      • Feb 13, 2017: Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
      • Oct 10, 2016: Aviragen Therapeutics to Host KOL Meeting on HRV Infections on October 13, 2016 in New York
      • Mar 03, 2015: Biota Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial
      • Mar 28, 2012: Biota Announces Positive Phase IIb Data In Asthma Patients With Human Rhinovirus Infection
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Rhinovirus Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Rhinovirus Infections - Pipeline by AIMM Therapeutics BV, H1 2017
  • Rhinovirus Infections - Pipeline by AstraZeneca Plc, H1 2017
  • Rhinovirus Infections - Pipeline by Aviragen Therapeutics Inc, H1 2017
  • Rhinovirus Infections - Pipeline by Biological Mimetics Inc, H1 2017
  • Rhinovirus Infections - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Rhinovirus Infections - Pipeline by Novartis AG, H1 2017
  • Rhinovirus Infections - Pipeline by Prokarium Ltd, H1 2017
  • Rhinovirus Infections - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Rhinovirus Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top